Maiwald strengthens team with Isenbruck SPC specialist

Mixed German IP firm Maiwald has strengthened its team with SPC expert Ulrike Herr. She joined in February from Isenbruck Bösl Hörschler, whose Munich office recently disbanded due to a string of departures.

7 February 2022 by Christina Schulze

Maiwald, Isenbruck Isenbruck has closed its Munich office. Some of its former patent attorneys joined Simmons & Simmons, while others moved to firms such as Maiwald ©willimeister/ADOBE STOCK

Ulrike Herr is a patent attorney specialising in polymer chemistry, pharmaceuticals and medical technology. She has many years of experience in SPC cases and complements a well-respected life science team at Maiwald. The IP firm already has a great deal of experience in this area.

Currently, the Maiwald life sciences team includes 42 patent attorneys. The firm has grown significantly this year, now counting 77 patent attorneys and lawyers in its ranks.

Maiwald hires Herr


Ulrike Herr

Previously, Ulrike Herr has worked side-by-side with Maiwald, representing plaintiff Hormosan/Lupin in the nullity proceedings against Gilead’s SPC on blockbuster Truvada.

Derk Vos, partner at Maiwald, says, “Ulrike is a reinforcement for Maiwald with her experience and expertise in chemistry, pharmaceuticals and especially supplementary protection certificates.”

Herr began her career as a patent and licensing counsel in the crop protection department at Bayer. After six years, she moved to the patent attorney firm Weickmann & Weickmann. Following this, she spent eight years at Isenbruck Bösl Hörschler.

Isenbruck disbands in Munich

Recently, Isenbruck Bösl Hörschler closed its Munich office. A team around the two Isenbruck partners Fritz Lahrtz and Stephanie Nottrott moved to Simmons & Simmons.

Other patent attorneys from the Munich office have left the firm, but JUVE Patent is not yet aware of their destination. Isenbruck retains offices in Mannheim and Düsseldorf, with 15 patent attorneys and two of counsel. The firm’s technical focus on chemical and pharmaceutical patents remains. However, its expertise in biotech is now significantly lower, with just two patent attorneys.